Plus Therapeutics plans to relaunch the CNSide cerebrospinal fluid assay, a diagnostic test for leptomeningeal metastases in the central nervous system (CNS), which detects circulating tumor cells and biomarkers using immunocytochemistry and fluorescence in situ hybridization. After acquiring CNSide from Biocept following its bankruptcy, Plus is securing necessary CLIA certification and state licenses to enable commercial availability in Texas before wider U.S. distribution. The test aims to improve current diagnostic methods considered outdated and inadequate for detecting CNS tumor spread. CNSide will also support clinical trials of Plus’s investigational radiotherapeutic Reyobiq for brain and CNS cancers.